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SUMMARY 
 
A second generation anti-ErbB2 ImmunoRNase, called Erb-hcAb-
RNase, was obtained by the fusion of Erb-hcAb, a human compact anti-
ErbB2 antibody, with human pancreatic ribonuclease (HP-RNase or 
RNase 1). 
We show herein that Erb-hcAb-RNase retains the enzymatic activity of 
human pancreatic RNase and specifically binds to ErbB2-positive cells 
with an affinity comparable to that of the parental Erb-hcAb. Moreover, 
this novel immunoRNase is endowed with an effective and selective 
antiproliferative action for ErbB2-positive tumor cells both in vitro and 
in vivo. Its antitumor activity is more potent than that of the parental 
Erb-hcAb as the novel immunoconjugate has acquired RNase-based 
cytotoxicity in addition to the inhibitory growth effects, antibody-
dependent and complement-dependent cytotoxicity of the compact 
antibody. 
Erb-hcAb-RNase could be a promising candidate for the immunotherapy 
of ErbB2-positive tumours as it combines the advantages of the first 
generation scFv-based immunoRNase with those of a fully functional 
antibody. 
   
V 
RIASSUNTO 
 
Una ImmunoRNasi anti-ErbB2 di seconda generazione, chiamata Erb-
hcAb-RNasi, è stata ottenuta mediante fusione dell’anticorpo compatto 
anti-ErbB2, Erb-hcAb, con la ribonucleasi pancreatica umana (HP-
RNasi o RNasi 1). 
In questo lavoro dimostriamo che Erb-hcAb-RNasi conserva l’attività 
enzimatica della ribonucleasi pancreatica umana e lega specificamente 
cellule ErbB2 positive con una affinità paragonabile a quella 
dell’anticorpo di origine Erb-hcAb. Inoltre, la nuova immunoRNasi 
possiede un’attività citotossica per cellule tumorali ErbB2-positive sia in 
vitro che in vivo. La sua attività antitumorale è più potente di quella 
dell’anticorpo di origine Erb-hcAb dato che il nuovo immunoconiugato 
ha acquisito la citotossicità mediata dalla ribonucleasi oltre agli effetti di 
inibizione della crescita ed alla citotossicità dipendente da anticorpo e da 
complemento dell’anticorpo di origine Erb-hcAb. Il costrutto Erb-hcAb-
RNasi potrebbe essere un promettente candidato da impiegare 
nell’immunoterapia dei tumori ErbB2-positivi poichè combina i 
vantaggi della prima generazione di immunoRNasi prodotta con scFv, 
con quelli di un anticorpo dotato di funzioni effettrici. 
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INTRODUCTION 
 
Immunotherapy is a precious strategy to overcome the limits of the 
conventional anti-cancer treatments. Indeed, targeting cancer cells via 
antibodies specific for tumor associated surface proteins could fulfil the lack 
of selectivity of radiotherapy and chemotherapy, and is a new interesting 
biomedical approach as it combines the rational drug design with the 
progress in understanding cancer biology. 
To date, several humanized monoclonal antibodies have achieved 
FDA approval, and an increasing number are undergoing clinical evaluation 
(1-4) (Table 1). A successful example of an approved humanized antibody is 
represented by Herceptin, the only humanized antibody widely used against 
ErbB2 positive carcinomas for immunotherapy (5).  
 
ErbB2 (Figure 1) is an attractive target for immunotherapy, as it is a 
transmembrane tyrosine kinase receptor, overexpressed on tumor cells of 
different origin, with a key role in the development of malignancy (6). 
Herceptin is currently used with success for breast cancer therapy; however, 
it can engender cardiotoxicity and a high fraction of breast cancer patients are 
resistant to Herceptin-treatment (7,8). 
Furthermore, also carcinomas with a high expression of ErbB2, such 
as non-small cell lung carcinoma, gastric and prostatic tumours, have been 
found to be resistant or much less sensitive to Herceptin treatment (9,10). 
 
A significant addition to the anticancer arsenal has been the 
construction of a new anti-ErbB2 immunoagent derived from a human, per se 
cytotoxic scFv, named Erbicin (11), and a human Fc domain from a human 
IgG1. This led to a fully human antitumour antibody, designed to be a 
reduced version of an IgG, with the antiproliferative effect of the scFv moiety 
on tumour target cells, combined with the ability of the Fc moiety to induce 
both antibody-dependent cellular cytotoxicity (ADCC) and complement-
dependent cytotoxicity (CDC).  
The engineered antibody has been called Erb-hcAb (Erbicin-human-
compact Antibody) (figure 2) for its “compact” size (100 kDa), compared 
with the full size (155 kDa) of a natural IgG. The smaller size should promote 
an increased extravascular diffusion and tumor penetration. 
It has been reported (12) that Erb-hcAb is capable of selective binding 
to malignant ErbB2-positive cells and of inhibiting their growth in vitro and 
in vivo, with no effects on ErbB2-negative cells. Moreover, Erb-hcAb is 
endowed with both ADCC and CDC cytotoxic effects.  
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Figure 1. Schematic representation of ErbB2 receptor 
 
 
                
Extracellular domain 
Intracellular domain 
Transmembrane domain 
Introduction 
 
 
4 
 
 
 
 
 
 
 
ERBICIN scFv
Fc (IgG1)
ERBICIN
CH3
CH2
CH1
CL
VL
VH
IgG1
M.W.= 155 kDa
M.W.= 100 kDa
M.W.= 27 kDa
 
Figure. 2-The construction of Erb-hcAb, a human compact anti-ErbB2 
antibody. Left: Erbicin, the parental  anti-ErbB2 scFv. Right: Erb-hcAb. 
VH and VL are the heavy and light chain variable domains, respectively, 
as derived from Erbicin. H, the hinge region with disulfide bridges. CH2 
and CH3 are the heavy chain constant domains of a human IgG1. Bottom: 
a full size IgG1 
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More recently, it has been shown that Erb-hcAb does not display the 
cardiotoxic effects of Herceptin in vitro on rat cardiomyocytes and in vivo on 
a mouse model (13), whereas Herceptin was found to be strongly toxic.  
This difference was found to be due to the different mechanism of 
action of the two antibodies: Herceptin, at difference with Erb-hcAb, induces 
apoptosis in cardiac cells (13). Finally, Erb-hcAb is active in vitro and in vivo 
against some Herceptin-resistant, ErbB2 positive breast cancer cell lines (14). 
 
 Targeted therapy can be accomplished also by using monoclonal 
antibodies (MAbs) equipped with radionuclides or toxins (15,16). 
Immunotoxins are anticancer agents made up of a recombinant antibody or an 
antibody fragment directed towards a unique cell surface protein and a potent 
bacterial toxin capable of inducing the death of target cells (17,18). 
However, problems have been encountered in clinical trials, especially 
for the toxicity and immunogenicity of the bacterial or plant toxins used for 
the immunotoxins (19,20). 
 
As an alternative to immunotoxins, ImmunoRNases (IR) have been 
proposed as more immuncompatible immunoagents. These are fusion proteins 
in which the toxin has been replaced by a ribonuclease. Mammalian RNases 
are expected to be not immunogenic and not systemically toxic, as they are 
pro-toxins, which become toxic only upon their internalization in target cells 
mediated by the antibody moiety (21-23). 
 
A fully human immunoRNase, denominated Erb-hRNase(Erbicin-
human-RNase) (Figure 3), was constructed through the fusion of Erbicin with 
human pancreatic RNase (HP-RNase or RNase 1) (24).  
The chimeric protein was found to retain the high binding affinity to 
ErbB2-positive cells of Erbicin and the enzymatic activity of native human 
pancreatic RNase. When tested in vitro on a series of malignant cells, Erb-
hRNase was found to discriminate between target and non-target cells, and to 
specifically inhibit the proliferation of ErbB2-positive cells, with a stronger 
cytotoxicity on cells with a higher level of ErbB2.  
Its antitumor activity has been also demonstrated in vivo on mice 
implanted with ErbB2-positive tumors (24,25). 
The antitumor action of Erb-hRNase is dependent on the ability of this 
molecule to reach the cytosol and degrade RNA but it is somewhat limited by 
the finding (26) that the enzymatic activity of Erb-hRNase is inhibited by the 
RNase inhibitor (RI). 
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Figure 3 Schematic representation of the human immunoRNase Erb-
hRNase (Erbicin-human-RNase). 
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In order to obtain a novel product, which is expected to be superior to 
the immunoagents currently used in the therapy of breast cancer, a novel 
immunoRNase has been designed, in which an Erbicin based scFv-Fc (Erb-
hcAb, see above) replaces the scFv of Erb-hRNase (Figure. 4).  
The latter should have the following advantages: the ability of 
inducing both ADCC and CDC, in addition to the RNase-based cytotoxicity; 
a prolonged half-life, due to its higher molecular size and the presence of the 
Fc; an increased avidity due to  
the presence of two scFv moieties. Furthermore, this novel immunoagent 
could be resistant to the action of RI, due to the steric hindrance generated by 
the presence of the larger antibody moiety. 
Here we report on the construction and characterization of a such 
novel fully human immunoRNase, made up of Erb-hcAb and HP-RNase, 
expressed in mammalian cell cultures.  
This new immunoconjugate, called Erb-hcAb-RNase, has shown to fully 
retain the binding ability, ADCC and CDC properties of Erb-hcAb and to 
acquire the RNase activity, thus inhibiting tumor cell proliferation in vitro and 
in vivo more efficiently than the parental Erb-hcAb. 
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Figure 4. Design of a novel immunoRNase in which an Erbicin based 
scFv-Fc (Erb-hcAb) replaces the scFv of Erb-hRNase. 
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MATERIALS AND METHODS  
 
2.1 Cell cultures and antibodies 
The SKBR3 cell line from human breast cancer and the A431 cell line 
from human epidermoid carcinoma were cultured in RPMI 1640 (Gibco 
BRL, Life Technologies, Paisley, UK). The TUBO cell line from a BALB-
neu T mouse-derived mammary lobular carcinoma (kindly provided by Dr G 
Forni, University of Turin, Italy) was grown in DMEM (Gibco BRL). The 
media were supplemented with 10% foetal bovine serum (20% for TUBO 
cells), 50 U ml
-1
 penicillin, 50 μg ml-1 streptomycin (all from Gibco BRL).  
The antibodies used were: Herceptin (Genentech, South San 
Francisco, CA, USA); affinity isolated IgGs from a rabbit anti-HP-RNase 
antiserum (from Igtech, Salerno, Italy); horseradish peroxidase (HRP)-
conjugated goat anti-rabbit immunoglobulins (Pierce, Rockford, IL, USA); 
HRP-conjugated goat anti-human affinity-isolated IgGs (Fc specific) 
(Sigma); Erb-hcAb was prepared as previously described (12). 
 
2.2 Peripheral blood lymphocytes 
Peripheral blood lymphocytes (PBL) were obtained from peripheral 
blood mononuclear cells (PBMC) isolated by centrifugation on Lymphoprep 
gradients (Axis Shield PoC AS, Oslo, Norway) from normal donor buffy 
coats obtained from the Blood Bank of the Medical School of the University 
of Naples 'Federico II'. After the separation, PBL were washed twice and 
incubated in RPMI 1640 medium (Gibco BRL) for 2 h at 37°C to remove 
adherent cells. The nonadherent cells were used as natural cytotoxic effectors 
without any additional treatment. 
 
2.3 Construction and production of the anti-ErbB2 Erb-hcAb-RNase 
The cDNA coding for the human compact antibody Erb-hcAb (12) 
was amplified from plasmid pIg1plus (R & D Systems, Minneapolis, USA) 
by PCR using as forward and reverse primers oligonucleotides containing at 
their 5' and 3’ ends a SalI and a NotI site, respectively: 5'-
ACGCGTCGACCAGGTGCAGCTGTTG-3';  
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5'-ATAAGAATGCGGCCGCTTTACCCGGAGACAGG-3'. The PCR 
fragment was then digested with SalI and NotI (New England Biolabs, 
Hertfordshire, UK) for cloning into the eukaryotic pCMV-ER-myc 
expression vector (Invitrogen) downstream to the leader Endoplasmic 
Reticulum (ER) signal peptide sequence. 
In order to obtain the chimeric construct, the gene fragment coding for 
the human pancreatic RNase was cloned downstream to the Erb-hcAb 
sequence by inserting a spacer encoding a 11-amino acid peptide linker 
(AAASGGPEGGS) between the scFv-Fc and the RNase. The cDNA coding 
for HP-RNase and the peptide spacer, previously generated (24) with NotI 
restriction sites at its 3’ and 5’ ends, was digested with NotI and cloned into 
the corresponding site of pCMV-ER-myc vector downstream to the sequence 
encoding the human Erb-hcAb.  
The correct directional insertion of the RNase gene in the NotI sites 
was assessed by digestion with suitable endonucleases (New England 
Biolabs). Sequence analyses confirmed the expected DNA sequence. 
The fusion protein was produced by transfecting 293 T (Human 
Embryonic Kidney) cells with the recombinant vector. In brief, cells grown in 
DMEM containing 10% FCS at 70–80% confluency were transfected with 
5 μg of expression vector by using the Superfect reagent (Qiagen, Valencia, 
CA, USA). Stable transfectants were selected in the presence of G418 
(Sigma) at a concentration of 1 mg ml
-1
. The expression of the antibody 
construct was determined in the culture medium by quantitative ELISA. For 
recombinant protein production, transfected 293T cells were expanded to 
near confluence in selective DMEM medium containing 0,5 mg/ml G418, 4 
mg/ml glucose, 10% foetal bovine serum, 50 U ml
-1
 penicillin, 50 μg ml-1 
streptomycin, and were then grown for 3–4 days in serum-free medium. 
The recombinant fusion protein, henceforth termed Erb-hcAb-RNase, 
secreted by transfected 293T cells, was purified from culture medium by 
affinity chromatography on a protein A-Ceramic Hyper D
®
F column (Pall 
Corporation Port Washington, NY) loaded with 300–500 ml of conditioned 
medium, washed with 10 volumes of 100 mM Tris-HCl, pH 8.0 containing 
0.5 M NaCl, and 10 volumes of 10 mM Tris-HCl, pH 8.0. The protein eluate 
was obtained with 50 mM glycine pH 3.0, and immediately neutralised with 
1/10 volume of 1 M Tris-HCl, pH 8.0. 
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2.4 RNase activity and inhibition  
RNase activity was tested with the acid-insoluble RNA precipitation 
assay as described previously (28) on yeast RNA (8 mg/ml). RNase 
zymograms, carried out on SDS-PAGE electropherograms, were performed 
as described previously (26). For inhibition assays, appropriate amounts of 
Erb-hcAb-RNase and Erb-hRNasewere pre-incubated with increasing 
concentrations of cRI at 37° C for 10 min before starting the activity test 
described above. Ribonuclease inhibitor was purchased from Promega 
(Madison, WI, USA); its concentration was determined as previously 
described (30). 
 
2.5 ELISA assays 
ErbB2-positive SKBR3 cells and ErbB2-negative A431 control cells, 
harvested in nonenzymatic dissociation solution (Sigma), were washed and 
transferred to U-bottom microtitre plates (1 x10
5
 cells per well). After 
blocking with PBS containing 6% bovine serum albumin (BSA), cells were 
incubated with conditioned medium or purified immunoagents in ELISA 
buffer (PBS/BSA 3%) for 90 min. The pelleted cells were washed, 
resuspended in 100 μl of ELISA buffer, and incubated with an anti-human 
IgG (Fc-specific) mAb (Sigma) for detection of Erb-hcAb and Erb-hcAb-
RNase. The latter was detected also with an anti-HP-RNase IgG antibody 
followed by HRP-conjugated goat anti-rabbit immunoglobulin. After 1 h, the 
plates were centrifuged, washed with ELISA buffer, and reacted with 
3,3',5,5'-tetramethylbenzidine (TMB) (Sigma). Binding values were 
determined from the absorbance at 450 nm, and reported as the mean of at 
least three determinations (s.d. 5%). 
 
2.6 Cell growth inhibition assays 
Cells were seeded in 96-well, flat-bottom plates; SKBR3 cells at a 
density of 1.5 x10
4
 well; A431 at a density of 5 x10
3
 well. After incubation at 
37° for 72h with the protein under test, viable cells were counted by the 
Trypan blue-exclusion test. Cell viability was determined in triplicate by 
using methyl tetrazolium (MTT) test (Sigma) according to the manufacturer’s 
recommendations. The resulting absorbance at 570 nm was measured in a  
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microplate counter (Multilabel Counter Victor 3, Perkin Elmer). Cell survival 
was expressed as percentage of viable cells in the presence of the protein 
under test, with respect to control cultures grown in the absence of the 
protein. Typically, standard deviations were below 5%. 
 
2.7 ADCC and CDC tests 
Target and control cells were detached from culture dishes with a cell 
dissociation solution (Sigma) and transferred to round-bottom 96-well plates 
(2 10
4
 cells per well). For ADCC assays, target or control cells were treated 
with the immunoagents (5 g ml
-1
 of serum-free medium) and peripheral 
blood lymphocytes (PBL) at 37°C for 3–4 h. For CDC assays, cells were 
incubated at 37°C with human serum. Cultures were performed in triplicate 
in a final volume of 200 l. Controls included target cells incubated in the 
absence of effector cells, or in the presence of either serum or immunoagent 
alone. Tumour cell lysis was determined by measuring the release of lactate 
dehydrogenase (LDH) using a LDH detection kit (Roche, Mannheim, 
Germany). ADCC or CDC was calculated as the percent of cytolysis 
measured in the presence of immunoagent and PBL or human serum, for 
ADCC and CDC, respectively, taking as 100% the maximal LDH release 
determined by lysis of target cells with 1% Triton X-100. 
 
2.8 In vivo antitumour activity 
All experiments were performed with 6-week-old female 
Balb/cAnNCrlBR mice (Charles River Laboratories, Calco, Italy). TUBO 
cells (5 10
5
) were suspended in 0.2 ml sterile PBS and injected 
subcutaneously (day 0) in the right paw. At day 7, when tumours started to 
appear, the mice were divided into three groups. At day 15, when tumours 
were clearly detectable, Erb-hcAb-RNase dissolved in PBS was administered 
i.p. at doses of 1.8 mg kg
-1
 of body weight for 7 times at 72 h intervals. The 
second group of animals was treated with equimolar doses (1.3 mg kg
-1
 of 
body weight ) of Erb-hcAb, dissolved in PBS, and administered i.p. for 7 
times at 72 h intervals. The third group of control animals was treated with 
identical volumes of sterile PBS. During the period of treatment, tumour 
volumes (V) were measured with caliper and calculated by the formula of 
rotational ellipsoid V=A xB
2
/2 (A is the axial diameter, B the rotational 
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diameter). All mice were maintained at the animal facility of the Department 
of Cellular and Molecular Biology and Pathology, University of Naples 
“Federico II”. Animal studies were conducted in accordance with the Italian 
regulation for experimentation on animals.  
All in vivo experiments were carried out with ethical committee 
approval and met the standards required by the UKCCCR guidelines (28). 
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RESULTS 
 
3.1 Production and purification of a novel fully human anti-ErbB2 
compact antibody-RNase conjugate 
A new human anti-ErbB2 immunoagent was generated by fusing 
human pancreatic RNase (HP-RNase) with the fully human anti-ErbB2 
compact antibody (Erb-hcAb) (12). The cDNAs coding for the human 
compact antibody Erb-hcAb and human pancreatic RNase were 
amplified by PCR and cloned into the eukaryotic pCMV-ER-myc 
expression vector. In particular, the cDNA encoding human pancreatic 
RNase was cloned downstream to the sequence encoding the carboxy 
terminus of the scFv-Fc (Erb-hcAb) by adding a spacer encoding a 11-
amino acid residue peptide linker (AAASGGPEGGS) to minimize the 
steric hindrance between the two moieties of the chimeric protein 
(figure 5). The recombinant plasmid, sequenced to confirm faithful 
cloning, was stably transfected in 293 T (Human Embryonic Kidney) 
cells, and the recombinant construct was expressed as a secretion 
product into the culture medium. Once selected by quantitative ELISA 
assays, the clone producing the highest levels of Erb-hcAb-RNase was 
used for the production of the chimeric immunoagent, which was then 
purified by affinity chromatography (see Methods). The immunoagent 
was named Erb-hcAb-RNase (anti-ErbB2 human compact antibody- 
RNase).  
 
 
3.2 Characterization of Erb-hcAb-RNase 
 
When Erb-hcAb-RNase was analysed by SDS–PAGE (figure 6), it 
was found to migrate under reducing conditions with the expected 
molecular size of about 70 kDa (figure. 6B), and as a dimer of about 
140 kDa under nonreducing conditions (figure. 6C). This result indicates 
that the fusion protein is expressed as a disulphide-linked dimer. 
Western blotting analyses performed with either an anti-human Fc or an 
anti-HP-RNase antibody demonstrated immunoreactivity of the 
purified, dimeric protein with a molecular size of 140 kDa (figure 6 D-
E).  
The fusion protein was then tested for enzymatic activity by a 
zymogram, developed using yeast RNA as a substrate. As illustrated in 
Results 
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figure. 6F, a single active band was detectable, corresponding to the size 
of Erb-hcAb-RNase.  
 
 
 
HP-RNase
CH3
CH2
Erbicin
HP-RNase
H CH2 CH3
Not ISal I Not I
CSE  r  b  i  c  i  nN HP-RNase
 
 
 
 
 
 
 
 
Figure 5  Schematic representation of the chimeric ImmunoRNase, Erb-
hcAb-RNase, obtained by fusing the human compact antibody Erb-hcAb, 
and the human pancreatic RNase. Erbicin, the human anti-ErbB2 scFv; H, 
hinge; CH2-CH3, the heavy constant domains of the human IgG1 Fc; S, the 
spacer peptide AAASGGPEGGS linking the scFv-Fc and the RNase 
moieties; HP-RNase, the RNase moiety 
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140 kDa
70 kDa
A      B      C       D      E      F
 
Figure 6. SDS–PAGE and Western blotting analyses of purified Erb-hcAb-
RNase. Erb-hcAb-RNase was run under reducing (lane B) or nonreducing 
(lane C) conditions; molecular weight standards are in lane A; Western 
blotting analyses of the purifed sample with an anti-human IgG1 (Fc 
specific) (lane D) or with the anti-human pancreatic RNase antibody (lane 
E); Zymogram of Erb-hcAb-RNase using yeast RNA as a substrate in lane F. 
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In a parallel assay the first generation anti-ErbB2 immunoRNase 
(Erb-hRNase), made up of the Erbicin scFv and HP-RNase, was used as 
a positive control (data not shown).  
The ribonucleolytic activity of the purified Erb-hcAb-RNase was 
further tested with the acid-insoluble RNA precipitation assay (28) , by 
which the chimeric immunoagent was found to have a specific activity 
of 730 ± 25 units/nmol. This result was confirmed for several 
preparations of the recombinant fusion protein. Because the specific 
activity of hErb-hRNase, i.e. the monomeric anti-ErbB2 immunoRNase, 
previously tested, is 950 ± 25 units/nmol (24), we can conclude that 
Erb-hcAb-RNase retains about 80% of the activity of the first 
generation ImmunoRNase (figure 7) . 
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Figure 7 Enzymatic activity of the immunoRNases (IR): the anti- ErbB2 
Erb-hcAb-RNase (orange) or ERB-hRNase (green)  
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To determine the sensitivity of Erb-hcAb-RNase to RI inhibition, 
the enzymatic assays were repeated in the absence or in the presence of 
increasing concentrations of RI. Erb-hRNase was used as a positive 
control, as it was previously found to be fully inhibited by RI (27).  
As shown in figure 8, the novel chimeric protein was found to be 
susceptible of inhibition by RI even though it was found to be less 
sensitive then the monomeric immunoRNase. Indeed, the new 
ImmunoRNase retains a residual 30% of the enzymatic activity even at 
a cRI/IR ratio of about 5, whereas the activity of the monomeric IR is 
completely inhibited at a cRI/IR ratio of about 1 (figure 8). 
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Figure 8. Effects of the RNase inhibitor (RI) on the enzymatic activity 
of the immunoRNases (IR).  
Inhibition by RI of the catalytic activity of the anti- ErbB2 Erb-hcAb-
RNase (circles) or ERB-hRNase (rhomboids) was measured at 
increasing RI/IR ratios 
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This result could be considered not surprising as the larger 
molecular size of the antibody fragment of Erb-hcAb-RNase with 
respect to that of the scFv in Erb-hRNase could hinder the interactions 
between RI and the RNase.  
 
When the ability of the recombinant fusion protein to bind to 
ErbB2-positive cells was analysed by ELISA assays (figure 9), Erb-
hcAb-RNase was found to fully retain the specificity and the affinity of 
the parental compact antibody for mammary carcinoma ErbB2-
overexpressing SKBR3 cells. As a negative control, we used A431 cells 
(from human epidermoid carcinoma), which express very low levels of 
ErbB2. The apparent binding affinity of Erb-hcAb-RNase for the ErbB2 
receptor, that is the concentration corresponding to half-maximal 
saturation, was about 1 nM, identical to that of the parental Erb-hcAb. 
These results demonstrate that the compact antibody and the RNase 
retain their biological functions in the chimeric protein. 
 
 
 
 
Results 
 
 
20 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Binding curves of Erb-hcAb-RNase or ERB-hcAb to ErbB2-
positive (SKBR3) and -negative (A431) cell lines. SKBR3 cells were tested 
by enzyme-linked immunoasorbent assay with Erb-hcAb-RNase (orange 
squares), or with Erb-hcAb (blue rhomboids), used as a control; A431 cells 
were tested as indicated above with Erb-hcAb-RNase or Erb-hcAb (empty 
squares and rhomboids, respectively). 
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3.3 Biological effects of Erb-hcAb-RNase on ErbB2-positive tumour cells  
 
To assess the in vitro effects of Erb-hcAb-RNase on tumour cell 
growth, the ErbB2-positive SKBR3 and the ErbB2-negative A431 cell 
lines were incubated with increasing concentrations of Erb-hcAb-RNase 
or ErbB-hcAb, used as a control. As shown in figure 10, Erb-hcAb-
RNase inhibited the growth of SKBR3 cells in a dose-dependent 
manner, showing an antiproliferative effect more potent than that 
observed for the parental Erb-hcAb. The immunoagent did not have any 
effect on the proliferation of ErbB2-negative A431 cells (see figure 10). 
 
To investigate whether Erb-hcAb-RNase was capable of recruiting 
immune effector functions in vitro, assays for cytolysis of tumour cells 
as induced by PBL, or complement, were performed. To determine the 
capacity of Erb-hcAb-RNase to selectively trigger ADCC towards 
antigen-expressing cells, SKBR3 and A431 cells were incubated for 3 h 
with increasing amounts of effector PBL in the absence or in the 
presence of Erb-hcAb-RNase (5 μg ml−1).  
We used as positive controls both Erb-hcAb and Herceptin. As shown in 
figure 11, Erb-hcAb-RNase lysed SKBR3 target cells in the presence of 
PBL with an efficacy comparable to that of the parental Erb-hcAb.  
The extent of lysis reached almost 80% of treated cells at a ratio of 
100:1 (effector to target cells), whereas Herceptin induced about 65% 
lysis at the same ratio.  
No effects were detected in parallel assays carried out with ErbB2-
negative A431 cells (data not shown), thus demonstrating the specificity 
of the Erb-hcAb-RNase-dependent cell-mediated cytolytic activity.  
Thus, we can conclude that the presence of the RNase in the new 
construct does not affect the interactions between the Fc region of Erb-
hcAb and the CD16 receptor of the natural killer cells.  
 
To test the ability of Erb-hcAb-RNase of inducing CDC against 
ErbB2-positive tumour cells, SKBR3 target cells were incubated for 6 h 
with Erb-hcAb-RNase (10 or 30 μg ml−1) in the absence or in the 
presence of human serum as a source of complement. As illustrated in 
Figure 12, Erb-hcAb-RNase was found to effectively lyse SKBR3 cells 
in the presence of serum in a similar fashion of Erb-hcAb, with an 
average specific lysis of 40% after 6 h.  
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CDC was not detected when ErbB2-negative A431 cells were incubated 
with Erb-hcAb-RNase and human serum (data not shown).  
 
Similarly, as previously reported (12, 32), no lysis was detectable when 
SKBR3 cells were treated with Herceptin in the presence of human 
serum (see figure 12).  
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Figure 10. In vitro effects of Erb-hcAb-RNase on cell survival. Dose 
response curves of ErbB2-positive SKBR3 (fully symbols), and ErbB2-
negative A431 cells (empty symbols), treated for 72 hours with Erb-
hcAb-RNase (squares).  
The effects of Erb-hcAb (rhomboids), used as a positive control, are 
also shown. 
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Figure 11 Antibody-dependent cytotoxicity assays of Erb-hcAb-RNase. 
SKBR3 cells treated with PBL as effector cells at four different ratios in 
the presence of Erb-hcAb-RNase (orange  bars), Erb-hcAb (blue bars) or 
Herceptin (striped bars) used as  positive controls.  
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Figure 12. Complement-dependent cytotoxicity assays of Erb-
hcAbRNase. 
SKBR3 cells were incubated for 6h in the presence of human 
serum as a source of complement with Erb-hcAb-RNase (orange 
bars), Erb-hcAb (blue bars), used as a positive control, or 
Herceptin (striped bars), used as a negative control, at 
concentrations of 10µg/ml
-1
and 30µg/ml
-1
.
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3.4 In vivo antitumor effects of Erb-hcAb-RNase 
 
For in vivo studies Erb-hcAb-RNase was tested on murine TUBO 
tumour cells expressing ErbB2 of rat origin (33).  
When administered to female mice, TUBO cells induce tumours very 
similar to the alveolar-type human lobular mammary carcinomas (34). 
In order to compare the in vivo antitumour efficacy of this novel 
immunoagent
 
with that of the parental Erb-hcAb, the
 
effects of equimolar 
doses of Erb-hcAb and Erb-hcAb-RNase were tested in parallel on the 
same experimental model.  
In particular, to detect the differential potency of the two immunoagents, 
they were administered at lower doses than those used for peritumoral 
administrations of Erb-hcAb in the previous experiment (13). when a 
dramatic reduction (96%) in tumor volume was observed.  
As shown in figure 13, the treatment of mice bearing TUBO tumours 
with seven doses, at 72 h intervals, of 1.8 mg kg
-1
 of Erb-hcAb-RNase 
induced a significant reduction (about 50 %) in tumour volume and 
showed more potent antitumor effects than those observed for the 
parental Erb-hcAb (doses of 1.3 mg kg
-1
).  
During the period of treatment, the animals did not show signs of wasting 
or other visible signs of toxicity. 
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 Figure 13. In vivo antitumor effects of Erb-hcAb-RNase.  
Tumor growth was followed in mice inoculated s.c. with 5x10
5
 
TUBO mammary carcinoma cells. Control animals (empty 
circles) were treated with sterile PBS solution.  
Treated animals were injected with Erb-hcAb-RNase (orange 
squares), starting at day 14. Seven doses, each of 1.8 mg kg-1 of 
body weight, were administered at 72 h intervals i.p.  
In a parallel experiment Erb-hcAb (blue rhomboids) was 
administered at equimolar doses (1.3 mg/kg 
-1
) as indicated for 
Erb-hcAb-RNase, for comparison. 
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DISCUSSION/CONCLUSIONS 
 
Immunotoxins (ITs), based on toxins fused to antibody moieties 
specifically reactive to a certain type of tumor cells, have been designed for a 
novel approach in anticancer therapy. However, the non-specific toxicity of 
ITs associated to vascular leak syndrome and/or hepatotoxicity, as well as the 
immunogenicity of their bacterial or plant toxins have often limited the 
outcome of immunotoxins as anticancer drugs (18-20). 
To circumvent these problems immunoRNases (IRs), based on the 
immunotoxin principle, have been proposed (21-23). In the immunoRNases, 
the toxin moiety of immunotoxins is replaced by a non-toxic and non-
immunogenic RNase, which becomes toxic only upon its internalization 
mediated by the antibody moiety in the target cells.  
We previously reported on a fully human immunoRNase obtained by 
fusing a human single-chain antibody fragment (scFv) and a human RNase 
(24), named Erb-hRNase, which is directed to the ErbB2 receptor, 
overexpressed in many carcinomas, especially in breast carcinoma (6,7). 
Erb-hRNase was found to exert a powerful and selective antitumor 
action in vitro and in vivo. However, its successful therapeutic use could be 
somewhat limited by the lack of antibody effector functions, as well as by its 
monovalent nature and by its small size (less than 50 kDa), which could be 
responsible for a reduced tumor retention and a faster clearance from the 
blood circulation, respectively. 
In this study, we report on the production and characterization of a 
novel second generation fully human IR targeting the ErbB2 receptor, called 
Erb-hcAb-RNase.  
It results from the fusion of the fully human anti-ErbB2 compact 
antibody Erb-hcAb (12) with HP-RNase. We have shown here that both the 
antibody and RNase moieties preserve their biological actions in the 
immunoconjugate. This is endowed with the following properties:  
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1. it recognises one of the most specific tumour-associated 
antigens, such as ErbB2, with an affinity comparable to that of 
the parental compact antibody; 
2.  it retains the enzymatic activity of the first generation 
immunoRNase (Erb-hRNase) but, at difference with the 
monovalent IR, it is only partially susceptible to RI inhibition;  
3. it displays effective antibody effector functions with an 
efficacy comparable to that of the parental Erb-hcAb; 
4.  it inhibits efficiently the proliferation of ErbB2-positive tumor 
cells both in vitro and in vivo with antitumor effects more 
potent than those observed for the parental compact antibody. 
The latter results can be explained by the additional toxic 
action of the internalized RNase;  
5. the size of Erb-hcAb-RNase should be better suited for 
therapeutic applications due to the potential prolonged half life 
with respect to the first generation scFv-based IR and to better 
penetration properties than full size IgG-toxin 
immunoconjugates. 
It has been already reported by Menzel and colleagues on a powerful 
anti-CD30 scFv-Fc-RNase, made up of a CD30 lymphoma specific human 
scFv-Fc fused to human pancreatic RNase, showing specific binding and in 
vitro cytotoxicity on CD30+ lymphoma cells at nM concentrations (24). 
However this IR was not tested for its effector functions (ADCC and CDC) 
and for its in vivo antitumor activity. 
 
To our knowledge, Erb-hcAb-RNase is to date the first fully human 
antibody-RNase to be constructed and tested with satisfactory results in vivo 
demonstrating for the first time that the presence of the RNase does not 
hinder the antibody effector functions (ADCC and CDC). 
 
On the basis of the effectiveness and selectivity of its antitumor action 
on target cells, Erb-hcAb-RNase represents a promising valuable tool in 
cancer therapy, thus supporting the hypothesis that the scFv-Fc-RNase format 
is the most appropriate for the production of a novel generation of IR better 
suited for therapeutic applications, as it combines the advantages of the first 
generation IR with those of functional relevant antibody domains. 
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